Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic equivalence study of clindamycin + tretinoin/Verisfield gel versus Acnatac and placebo in acne vulgaris
2022-003070-23Phase 3Active
- Sponsor
- Verisfield
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tretinoin and clindamycin in acne vulgaris (3 arms), sponsored by Verisfield. Primary endpoint: Percent change in facial inflammatory lesion count at Week 12. Started Dec 2022; status: active.
02
Drugs
tretinoinclindamycin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2022-003070-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003070-23.